The Challenge of Understanding Biotech: Sifting Through the Fog and Jargon


(Page 3 of 3)

my request for a copy of this report has been unfulfilled. These articles may be well researched and written, but price and/or exclusivity have prevented me from determining this for myself.

Poorly explained phrases gum up a clear understanding of relevant issues in the industry. Meaningless jargon too often replaces clear insights. In one recent report by Ernst and Young, titled “Beyond Borders: Global Biotechnology Report 2010,” I waded through the muck created by the following phrases (not all written by E&Y): “the new normal” “Pharma 3.0” “precompetitive collaboration” “open innovation approaches” “asset-centric financing” “constituents of the biotech ecosystem” “proof-of-concept value inflection point” “fail fast” “force multipliers” and “lean proof of concept.”

Here is an “insight” from the same report, discussing Eli Lilly’s Chorus program: “We did not follow the typical path to proof of concept—using very small studies that are poorly controlled and rely on unvalidated endpoints to give some suggestion of efficacy. Instead, we designed well-controlled studies to derive truly meaningful data using validated surrogates or bona fide clinical endpoints.” Are there industry people out there who deliberately set out to do poorly controlled studies on unvalidated endpoints for their personal amusement? Is this why Big Pharma has gotten itself into such Big Trouble? What does it say about an industry if doing well-designed studies with clear endpoints is supposed to be a revolutionary advance?

According to several contributors to this 2010 E&Y report, “our industry is at a point in its evolution when we have limited resources and large unmet needs.” Did I miss the point when we had unlimited resources? Was that the day I overslept? And when was there was a small number of unmet needs?

Years ago, a thoughtful co-worker passed along to me a copy of a game called “BS Bingo” that was designed to keep you awake during boring meetings and conference calls. Many of you will have played this game over the years. It consists of a 5 x 5 grid of current industry buzzwords and is designed to help focus your attention during those meetings (and we’ve all been there) where the speakers trot out every trite phrase and trendy jargon term currently circulating in the industry. The version I was given in the early ’90s included “synergy” “win-win” “think outside of the box” “value added” and “proactive.” Every time the speaker used one of these terms, you checked it off on your grid. If you successfully checked off a full row of terms, you were supposed to yell out “Bullsh*t” and bring the meeting to a thankfully foreshortened conclusion. It’s clearly time to update my copy.

People who present themselves as industry leaders have a responsibility to explain plainly how their conclusions are derived, and to communicate clearly with those whom they seek to align with their viewpoints. We should refuse to accept ill-defined or inaccessible numbers, meaningless statistics, and challenge those who retreat to the illusionary safety of jargon to clarify what they really mean.

Single PageCurrently on Page: 1 2 3 previous page

Stewart Lyman is Owner and Manager of Lyman BioPharma Consulting LLC in Seattle. He provides strategic advice to clients on their research programs, collaboration management issues, as well as preclinical data reviews. Follow @

Trending on Xconomy

By posting a comment, you agree to our terms and conditions.

7 responses to “The Challenge of Understanding Biotech: Sifting Through the Fog and Jargon”

  1. natalie says:


  2. Hilarious and unfortunately all too true. I have had similar thoughts as yours Stuart but you have done a great job of getting it down on “virtual” paper for all to enjoy.

  3. JC says:

    I’m amazed by the continuous “group think” inside the industry and companies vying for approval themselves. They are so sure they will be approved they bet the farm, build out expensive facilities and hire loads of people who all too soon will be laid off.

    Always makes me wonder what they know that no one else does, but alas the FDA continuously surprises us with delays or outright dis-approvals (Amylin the most recent notable).

    With all of the sophistication, investment and science of our modern era, I find the process, expectations and execution of getting products approved still archaic.

  4. Peter says:

    Nice job! I always try to read the Numbers Guy, Carl Bialik, in the Wall Street Journal. As a mathmetician he tries to rationalize some of the numbers that frequently are quoted. For instance, he recently wrote about and largely debunked the oft-cited “statistic” that 10% of the drugs sold are counterfeit: We need more fact checkers, but as you point out, it is not easy to trace down the origins of many of these numbers.

    The best example of “group think” is what happens in big pharma when senior management changes its philosophy on the “right” way to discover and develop drugs. They often end up criticizing their own ideas of a few years earlier and then expect the entire organization to adopt their “new” ideas. Of course anyone who disagrees is criticized for not being a “team” player and is usually swept out in the next round of layoffs.

  5. John says:

    Great stuff, well presented. But it isn’t only the life science industry that plays fast and loose with facts and language. Yesterday I read of a highly successful aid program that distributed $200M to 25M people. That $8 per person was life-changing aid.

    Is part of our “evolving” journalism industry dropping its fact checking role?

  6. Anthony Rodriguez says:

    In every sector from academia to politics, people are irresponsible with numbers. The lack of transparency with the information that is pushed in today’s web-based society is sad. Like Stewart, I will all too often stop my due diligence as soon as the source asks for a credit card number. Its just easier and cheaper to take these statements at face value. I applaud journals like PLoS who allow for researchers to post their RAW data online with their article free to access for anyone. Will we ever see something like this become a standard across all sectors? I hope so, but I am not holding my breath.